What is TesoRx Pharma?
TesoRx Pharma operates as a clinical-stage biopharmaceutical enterprise dedicated to the development of advanced oral drug delivery systems. The company's core competency lies in its ability to reformulate existing therapeutics and develop novel compounds that address unmet medical needs, particularly where current treatment options are sub-optimal or limited. By leveraging decades of research and development, TesoRx Pharma focuses on enhancing the bioavailability and efficacy of drugs, thereby improving patient outcomes and expanding the therapeutic window for various conditions. Their market position is defined by a commitment to scientific rigor and a portfolio that bridges the gap between laboratory discovery and commercial-ready clinical applications.
How much funding has TesoRx Pharma raised?
TesoRx Pharma has raised a total of $20.7M across 5 funding rounds:
Unspecified
$5.9M
Unspecified
$3.9M
Series B
$10M
Private Equity
$697K
Debt
$150K
Unspecified (2012): $5.9M, investors not publicly disclosed
Unspecified (2013): $3.9M, investors not publicly disclosed
Series B (2014): $10M supported by Undisclosed
Private Equity (2016): $697K, investors not publicly disclosed
Debt (2020): $150K backed by PPP
Key Investors in TesoRx Pharma
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for TesoRx Pharma?
With the recent strategic investment, TesoRx Pharma is poised to scale its clinical trial operations and expand its therapeutic portfolio. The company's strategic roadmap likely involves the advancement of its lead candidates through late-stage clinical testing, a critical phase for securing regulatory approval and eventual market entry. Furthermore, the firm is expected to leverage its oral delivery platform to explore potential licensing agreements or strategic partnerships with larger pharmaceutical entities, which could provide the necessary infrastructure for large-scale commercialization. As the company continues to refine its drug delivery technology, the focus will remain on achieving key clinical milestones that validate the platform's scalability and therapeutic utility in diverse medical markets.
See full TesoRx Pharma company page
